後天性自己免疫性溶血性貧血の世界市場レポート 2025年

後天性自己免疫性溶血性貧血市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4％で28億8,000万米ドルに成長します。予測期間における成長の原動力は、自己免疫疾患の罹患率の上昇、補体系の役割に対する理解の深まり、バイオファーマ企業と学術機関の協力関係の強化、個別化医療の利用の増加、高齢化などが予想されます。この時期の主要動向としては、標的生物製剤の採用、補体経路阻害剤の進歩、疾病管理におけるAIとデータ分析の活用、AI主導の臨床検査デザイン、希少疾病用医薬品開発の革新などが挙げられます。

自己免疫疾患の有病率の増加は、今後数年間の後天性自己免疫性溶血性貧血（AIHA）市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が体内の健康な細胞や組織を有害な侵入者とみなして誤って攻撃することで発症します。この自己免疫疾患の増加は、主に免疫系の調節を乱す環境要因の増加やライフスタイルの変化に関連しています。これらの疾患の有病率の増加は、後天性自己免疫性溶血性貧血の発症率の増加につながります。なぜなら、自己免疫疾患の患者は、免疫系の調節障害により二次性AIHAを発症する可能性が高いからです。例えば、2022年に米国の自己免疫レジストリは、複数の自己免疫疾患と診断された患者の割合が2021年の52％から2022年には55％に増加したと報告しています。このように、自己免疫疾患の有病率の増加は、後天性AIHA市場の拡大に寄与するであると考えられます。

後天性自己免疫性溶血性貧血市場の企業は、治療成績を改善し、副作用を最小限に抑え、患者により個別化された治療を提供するために、ヒト化モノクローナル抗体を含む標的療法の進歩に注目しています。ヒト化モノクローナル抗体は、ヒト抗体に酷似するように設計された実験室レベルのタンパク質であり、その構造の大部分はヒトであるが、免疫系の拒絶反応を抑えながら特定の抗原を標的とするのに役立つ非ヒト（多くの場合マウス）抗体をわずかに含んでいます。例えば、2022年2月、フランスに本社を置くヘルスケア企業Sanofiは、自己免疫性溶血性貧血の希少型である寒冷凝集素病（CAD）に対する最初で唯一の治療であるEnjaymo（sutimlimab-jome）のFDA承認を取得しました。この治療は古典的補体経路のC1を選択的に阻害し、免疫系が健康な赤血球を攻撃するのを防ぎ、CAD患者における輸血の必要性を減少させています。エンジェイモはC1活性化溶血を特異的に標的とする一方、レクチンと代替補体経路には影響を与えないです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の後天性自己免疫性溶血性貧血PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の後天性自己免疫性溶血性貧血市場：成長率分析
• 世界の後天性自己免疫性溶血性貧血市場の実績：規模と成長、2019～2024年
• 世界の後天性自己免疫性溶血性貧血市場の予測：規模と成長、2024～2029年、2034年
• 世界の後天性自己免疫性溶血性貧血総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の後天性自己免疫性溶血性貧血市場：診断方法別、実績と予測、2019～2024年、2024～2029年、2034年
• 全血球数
• 末梢血塗抹サンプル
• 直接クームス検査
• 間接クームス検査
• 世界の後天性自己免疫性溶血性貧血市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• 免疫抑制剤
• 静脈内免疫グロブリン
• リツキシマブ
• 世界の後天性自己免疫性溶血性貧血市場：重症度別、実績と予測、2019～2024年、2024～2029年、2034年
• 軽度
• 中等度
• 重度
• 世界の後天性自己免疫性溶血性貧血市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 研究機関
• 世界の後天性自己免疫性溶血性貧血市場、全血球計算のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヘモグロビン値
• ヘマトクリット（HCT）
• 網状赤血球数
• 白血球数
• 血小板数
• 世界の後天性自己免疫性溶血性貧血市場、末梢血塗抹サンプルのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 球状赤血球
• 多色性
• 分裂細胞
• 網状赤血球数の増加
• 世界の後天性自己免疫性溶血性貧血市場、直接クームス検査のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫グロブリンGクームス検査
• 免疫グロブリンMクームス検査
• 補体クームス検査
• 世界の後天性自己免疫性溶血性貧血市場、間接クームス検査のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アロ抗体のスクリーニング
• 感作抗体の検出
• 交差適合検査

第7章 地域別・国別分析

• 世界の後天性自己免疫性溶血性貧血市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の後天性自己免疫性溶血性貧血市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 後天性自己免疫性溶血性貧血市場：競合情勢
• 後天性自己免疫性溶血性貧血市場：企業プロファイル
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Sanofi SA
  • Novartis AG

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Incyte Corporation
• Alexion Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• Annexon Inc.
• Rigel Pharmaceuticals Inc.
• Nanjing IASO BIoTherapeutics Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Momenta Pharmaceuticals Inc.
• Zenas BioPharma Inc.
• Immunovant Sciences GmbH
• Alpine Immune Sciences Inc.
• Agios Pharmaceuticals Inc.
• Rakshit Drugs Private Limited
• Aarti Pharmalabs Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 後天性自己免疫性溶血性貧血市場、2029年：新たな機会を提供する国
• 後天性自己免疫性溶血性貧血市場、2029年：新たな機会を提供するセグメント
• 後天性自己免疫性溶血性貧血市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Acquired autoimmune hemolytic anemia (AIHA) is a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells, leading to anemia. It is often triggered by infections, autoimmune diseases, certain cancers, or specific medications, and can develop either suddenly or gradually. This occurs when the body produces antibodies that target its own red blood cells, resulting in hemolysis, or the early destruction of those cells.

The primary diagnostic methods for acquired autoimmune hemolytic anemia include a complete blood count, peripheral blood smear, direct Coombs test, and indirect Coombs test. A complete blood count (CBC) helps detect anemia by identifying low hemoglobin and hematocrit levels, as well as a higher reticulocyte count, which indicates increased red blood cell destruction. Treatment options vary and can include corticosteroids, immunosuppressive drugs, intravenous immunoglobulin, and rituximab. The severity of the disease ranges from mild to moderate to severe. Key end users of these diagnostic and treatment services include hospitals, specialty clinics, and research institutions.

The acquired autoimmune hemolytic anemia market research report is one of a series of new reports from The Business Research Company that provides acquired autoimmune hemolytic anemia market statistics, including the acquired autoimmune hemolytic anemia industry global market size, regional shares, competitors with the acquired autoimmune hemolytic anemia market share, detailed acquired autoimmune hemolytic anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the acquired autoimmune hemolytic anemia industry. This acquired autoimmune hemolytic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acquired autoimmune hemolytic anemia market size has grown strongly in recent years. It will grow from $2.01 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to factors such as higher diagnosis rates, an increasing occurrence of secondary AIHA, the expansion of hospital hematology units, support from governments and regulatory bodies, and growing investments in hematology.

The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, a better understanding of the complement system's role, increased collaboration between biopharma companies and academic institutions, a rise in the use of personalized medicine, and an aging population. Key trends during this period include the adoption of targeted biologic therapies, progress in complement pathway inhibitors, the use of AI and data analytics in disease management, AI-driven clinical trial design, and innovations in orphan drug development.

The growing prevalence of autoimmune disorders is expected to drive the growth of the acquired autoimmune hemolytic anemia (AIHA) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own healthy cells and tissues, viewing them as harmful invaders. This rise in autoimmune disorders is mainly linked to increased environmental factors and lifestyle changes that disrupt immune system regulation. The increasing prevalence of these disorders leads to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For example, in 2022, the autoimmune registry in the United States reported that the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. As such, the growing prevalence of autoimmune disorders will contribute to the expansion of the acquired AIHA market.

Companies in the acquired autoimmune hemolytic anemia market are focusing on advances in targeted therapies, including humanized monoclonal antibodies, to improve treatment outcomes, minimize side effects, and offer more personalized care for patients. Humanized monoclonal antibodies are laboratory-engineered proteins designed to closely resemble human antibodies, with a structure that is mostly human but contains small portions of non-human (often mouse) antibodies to help target specific antigens while reducing immune system rejection. For instance, in February 2022, Sanofi, a healthcare company based in France, received FDA approval for Enjaymo (sutimlimab-jome), the first and only treatment for cold agglutinin disease (CAD), a rare form of autoimmune hemolytic anemia. This treatment selectively inhibits C1s in the classical complement pathway, preventing the immune system from attacking healthy red blood cells and reducing the need for transfusions in CAD patients. Enjaymo specifically targets C1-activated hemolysis while leaving the lectin and alternative complement pathways unaffected.

In September 2023, Bristol Myers Squibb, a biopharmaceutical company based in the U.S., acquired the Asian market rights for obexelimab, a bifunctional monoclonal antibody from Zenas BioPharma, for $50 million. This acquisition aims to expand Bristol Myers Squibb's immunology portfolio and strengthen its position in the Asian market for autoimmune disease treatments. Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company that focuses on developing immunology therapies for autoimmune diseases, including acquired autoimmune hemolytic anemia.

Major players in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd.

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in acquired autoimmune hemolytic anemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acquired autoimmune hemolytic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired autoimmune hemolytic anemia market consists of revenues earned by entities by providing services such as diagnosis services, treatment and medication services, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired autoimmune hemolytic anemia market also includes sales of prednisone, and methylprednisolone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Autoimmune Hemolytic Anemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired autoimmune hemolytic anemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acquired autoimmune hemolytic anemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired autoimmune hemolytic anemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis Method: Complete Blood Count; Peripheral Blood Smear; Direct Coombs Test; Indirect Coombs Test
• 2) By Treatment Type: Corticosteroids; Immunosuppressive Agents; Intravenous Immunoglobulin; Rituximab
• 3) By Severity: Mild; Moderate; Severe
• 4) By End User: Hospitals; Specialty Clinics; Research Institutions
• Subsegment:
• 1) By Complete Blood Count: Hemoglobin Level; Hematocrit (HCT); Reticulocyte Count; White Blood Cell Count; Platelet Count
• 2) By Peripheral Blood Smear: Spherocytes; Polychromasia; Schistocytes; Increased Reticulocyte Count
• 3) By Direct Coombs Test: Immunoglobulin G Coombs Test; Immunoglobulin M Coombs Test; Complement Coombs Test
• 4) By Indirect Coombs Test: Screening For Alloantibodies; Detection Of Sensitizing Antibodies; Crossmatch Testing
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Sanofi SA; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acquired Autoimmune Hemolytic Anemia Market Characteristics

3. Acquired Autoimmune Hemolytic Anemia Market Trends And Strategies

4. Acquired Autoimmune Hemolytic Anemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acquired Autoimmune Hemolytic Anemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acquired Autoimmune Hemolytic Anemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acquired Autoimmune Hemolytic Anemia Market Growth Rate Analysis
• 5.4. Global Acquired Autoimmune Hemolytic Anemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acquired Autoimmune Hemolytic Anemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acquired Autoimmune Hemolytic Anemia Total Addressable Market (TAM)

6. Acquired Autoimmune Hemolytic Anemia Market Segmentation

• 6.1. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Blood Count
• Peripheral Blood Smear
• Direct Coombs Test
• Indirect Coombs Test
• 6.2. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Agents
• Intravenous Immunoglobulin
• Rituximab
• 6.3. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild
• Moderate
• Severe
• 6.4. Global Acquired Autoimmune Hemolytic Anemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutions
• 6.5. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Complete Blood Count, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Level
• Hematocrit (HCT)
• Reticulocyte Count
• White Blood Cell Count
• Platelet Count
• 6.6. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Peripheral Blood Smear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spherocytes
• Polychromasia
• Schistocytes
• Increased Reticulocyte Count
• 6.7. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Direct Coombs Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin G Coombs Test
• Immunoglobulin M Coombs Test
• Complement Coombs Test
• 6.8. Global Acquired Autoimmune Hemolytic Anemia Market, Sub-Segmentation Of Indirect Coombs Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening For Alloantibodies
• Detection Of Sensitizing Antibodies
• Crossmatch Testing

7. Acquired Autoimmune Hemolytic Anemia Market Regional And Country Analysis

• 7.1. Global Acquired Autoimmune Hemolytic Anemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acquired Autoimmune Hemolytic Anemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market

• 8.1. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acquired Autoimmune Hemolytic Anemia Market

• 9.1. China Acquired Autoimmune Hemolytic Anemia Market Overview
• 9.2. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acquired Autoimmune Hemolytic Anemia Market

• 10.1. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acquired Autoimmune Hemolytic Anemia Market

• 11.1. Japan Acquired Autoimmune Hemolytic Anemia Market Overview
• 11.2. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acquired Autoimmune Hemolytic Anemia Market

• 12.1. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acquired Autoimmune Hemolytic Anemia Market

• 13.1. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acquired Autoimmune Hemolytic Anemia Market

• 14.1. South Korea Acquired Autoimmune Hemolytic Anemia Market Overview
• 14.2. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acquired Autoimmune Hemolytic Anemia Market

• 15.1. Western Europe Acquired Autoimmune Hemolytic Anemia Market Overview
• 15.2. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acquired Autoimmune Hemolytic Anemia Market

• 16.1. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acquired Autoimmune Hemolytic Anemia Market

• 17.1. Germany Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acquired Autoimmune Hemolytic Anemia Market

• 18.1. France Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acquired Autoimmune Hemolytic Anemia Market

• 19.1. Italy Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acquired Autoimmune Hemolytic Anemia Market

• 20.1. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market

• 21.1. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market Overview
• 21.2. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acquired Autoimmune Hemolytic Anemia Market

• 22.1. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acquired Autoimmune Hemolytic Anemia Market

• 23.1. North America Acquired Autoimmune Hemolytic Anemia Market Overview
• 23.2. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acquired Autoimmune Hemolytic Anemia Market

• 24.1. USA Acquired Autoimmune Hemolytic Anemia Market Overview
• 24.2. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acquired Autoimmune Hemolytic Anemia Market

• 25.1. Canada Acquired Autoimmune Hemolytic Anemia Market Overview
• 25.2. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acquired Autoimmune Hemolytic Anemia Market

• 26.1. South America Acquired Autoimmune Hemolytic Anemia Market Overview
• 26.2. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acquired Autoimmune Hemolytic Anemia Market

• 27.1. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acquired Autoimmune Hemolytic Anemia Market

• 28.1. Middle East Acquired Autoimmune Hemolytic Anemia Market Overview
• 28.2. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acquired Autoimmune Hemolytic Anemia Market

• 29.1. Africa Acquired Autoimmune Hemolytic Anemia Market Overview
• 29.2. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acquired Autoimmune Hemolytic Anemia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acquired Autoimmune Hemolytic Anemia Market Competitive Landscape And Company Profiles

• 30.1. Acquired Autoimmune Hemolytic Anemia Market Competitive Landscape
• 30.2. Acquired Autoimmune Hemolytic Anemia Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Acquired Autoimmune Hemolytic Anemia Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Incyte Corporation
• 31.3. Alexion Pharmaceuticals Inc.
• 31.4. BioCryst Pharmaceuticals Inc.
• 31.5. Annexon Inc.
• 31.6. Rigel Pharmaceuticals Inc.
• 31.7. Nanjing IASO Biotherapeutics Co. Ltd.
• 31.8. Apellis Pharmaceuticals Inc.
• 31.9. Momenta Pharmaceuticals Inc.
• 31.10. Zenas BioPharma Inc.
• 31.11. Immunovant Sciences GmbH
• 31.12. Alpine Immune Sciences Inc.
• 31.13. Agios Pharmaceuticals Inc.
• 31.14. Rakshit Drugs Private Limited
• 31.15. Aarti Pharmalabs Ltd.

32. Global Acquired Autoimmune Hemolytic Anemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acquired Autoimmune Hemolytic Anemia Market

34. Recent Developments In The Acquired Autoimmune Hemolytic Anemia Market

35. Acquired Autoimmune Hemolytic Anemia Market High Potential Countries, Segments and Strategies

• 35.1 Acquired Autoimmune Hemolytic Anemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acquired Autoimmune Hemolytic Anemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acquired Autoimmune Hemolytic Anemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer